Jeff Lewis
Sat, April 4, 2026 astatine 7:16 AM CDT 1 min read
Autolus Therapeutics plc (NASDAQ:AUTL) is 1 of the
On March 27, 2026, Autolus Therapeutics plc (NASDAQ:AUTL) reported 4th fourth EPS of (34c), compared to the (43c) statement estimate, with gross of $24.29 cardinal versus $23.29 cardinal consensus. Chief Executive Officer Christian Itin said that Autolus Therapeutics plc (NASDAQ:AUTL) had a “strong archetypal twelvemonth of launch” for AUCATZYL successful the U.S., highlighting the commercialized execution, merchandise delivery, and real-world information showing objective enactment with debased rates of high-grade CRS and ICANS. Chief Executive Officer Christian Itin added that the affirmative lawsuit acquisition should enactment the aboriginal maturation of AUCATZYL.
Photo by National Cancer Institute connected Unsplash
Autolus Therapeutics plc (NASDAQ:AUTL) develops T compartment therapies for crab and autoimmune diseases successful the United Kingdom and internationally.
While we admit the imaginable of AUTL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey connected Google News.

2 weeks ago
9





English (CA) ·
English (US) ·
Spanish (MX) ·